Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jan 26, 2024; 16(1): 1-6
Published online Jan 26, 2024. doi: 10.4252/wjsc.v16.i1.1
Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics
Hang-Qi Hu, Xi-Yan Xin, Yu-Tian Zhu, Rui-Wen Fan, Hao-Lin Zhang, Yang Ye, Dong Li
Hang-Qi Hu, Xi-Yan Xin, Yu-Tian Zhu, Rui-Wen Fan, Hao-Lin Zhang, Yang Ye, Dong Li, Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing 100191, China
Co-corresponding authors: Yang Ye and Dong Li.
Author contributions: Hu HQ wrote the first draft of the manuscript; Xin XY, Zhu YT, Fan RW, and Zhang HL contributed to review and editing; Ye Y and Li D conceived, reviewed, and revised this paper. Ye Y and Li D contributed equally and share the corresponding authorship.
Supported by the Cohort Construction Project of Peking University Third Hospital, No. BYSYDL2022013; Clinical Key Project of Peking University Third Hospital, No. BYSY2023049; Special Grant for Capital Health Research and Development, No. 2022-2-4097; and Funding from State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, No. BYSYSZKF2023027.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang Ye, PhD, Assistant Professor, Department of Traditional Chinese Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. yeyang89@bjmu.edu.cn
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: December 5, 2023
Revised: December 9, 2023
Accepted: December 26, 2023
Article in press: December 26, 2023
Published online: January 26, 2024
Processing time: 79 Days and 17.5 Hours
Core Tip

Core Tip: Premature ovarian insufficiency (POI) is an increasing cause of infertility globally, particularly among younger women, with profound effects on reproductive function and health. With limited treatment options and unsatisfactory results, the use of mesenchymal stem cell (MSC) therapies offers promising transformative approaches to restore ovarian function and enhance reproductive health in women. This article provides a concise overview and evidence of the potential benefits of MSC therapy for POI.